<DOC>
	<DOC>NCT00529503</DOC>
	<brief_summary>This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.</brief_summary>
	<brief_title>A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Confirmed diagnosis of de novo or transformed DLBCL, or follicular grade 3b lymphoma. Received at least four cycles of firstline therapy with RCHOP, or equivalent. Best clinical response to firstline therapy of stable disease, partial response, or complete response. At least one measureable lesion that is both greater than or equal to 1.5cm by radiographic imaging and by positive FDGPET scan. Leptomeningeal or central nervous system lymphoma. Received any therapy for relapsed or progressive disease except for local radiation, steroids, or rituximab. Received a hematopoietic stem cell transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Antigens, CD40</keyword>
	<keyword>Antibody, Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
</DOC>